奎斯特診療 DGX 深 滬
已收盤 02-06 16:00:00 美东时间
190.71
-1.590
-0.83%
華盛通- 最 高193.60
- 今 開193.20
- 成交量 109.95万股
- 最 低 189.94
- 昨 收 192.30
- 總市值 212.15亿
- 52周最高 196.75
- 市盈率 靜 24.88
- 換手率 0.99%
- 52周最低 154.80
- 委 比 -40.85%
- 總股本 1.11亿
- 歷史最高 196.75
- 量 比 0.92
- 振 幅 1.90%
- 歷史最低 18.005
- 每 手 1
- 風險率 7.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quest Diagnostics Launches Blood Test Using Advanced Flow Cytometry Methods To Assess Measurable Residual Disease In Patients With Blood Cancer Myeloma
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testingSECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading
02-02 21:54
Quest Diagnostics Launches Blood-Based Flow Cytometry MRD Test for Myeloma
Quest Diagnostics Launches Blood-Based Flow Cytometry MRD Test for Myeloma Quest Diagnostics Incorporated has announced the launch of a novel blood test utilizing advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with multiple myeloma. The Quest Flow Cytometry M
02-02 21:52
How Do Investors Really Feel About Quest Diagnostics Inc?
Quest Diagnostics Inc's (NYSE:DGX) short interest as a percent of float has ris...
01-17 00:00
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J., Dec. 19, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, ...
2025-12-20 04:20
Octave Bioscience Enters Strategic Collaboration With Quest Diagnostics To Make The Octave MS Disease Activity Test Widely Accessible Through Quest's Nationwide Specimen-Collection Network
Collaboration enables patients to access the Octave MSDA test at Quest's approximately 7,000 patient access sites across the U.S. and establishes a pathway to introduce additional tests from Octave's precision neurology
2025-12-01 21:37
电话会总结 ｜ Quest(DGX)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Quest Diagnostics第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 第三季度合并营收28.2亿美元，同比增长13.1% - 有机营收增长6.8%，主要由产品需求、收购和消费者渠道扩张推动 - 诊断信息服务营收同比增长13.5% **盈利能力：** - 报告营业利润3.86亿美元，营业利润率13.7%（去年同期3.3亿美元，13.3%） - 调整后营业利润4.58亿美元，营业利润率16.3%（去年同期3.85亿美元，15.5%） - 报告每股收益2.16美元（去年同期1.99美元） - 调整
2025-12-01 12:13
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
Hims & Hers launches Labs, offering annual biomarker testing plans with doctor-developed guidance and expanded diagnostics planned across key health categories.
2025-11-15 02:35
Quest Diagnostics declares $0.80 dividend
Quest Diagnostics (DGX) declared $0.80/share quarterly dividend, in line with previous. Forward yield 1.69% Payable Jan. 28; for shareholders of record Jan. 13; ex-div Jan. 13. See DGX Dividend Scorec...
2025-11-12 05:23
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Nov. 11, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cas...
2025-11-12 05:22
Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
SECAUCUS, N.J., Nov. 3, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and C...
2025-11-04 05:09
